BioNexus Gene Lab Corp. cash flow to debt ratio of -1.04K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioNexus Gene Lab Corp.'s free cash flow has increased -23.80% from $-2.46M last year to $-1.88M, signaling increasing performance

BioNexus Gene Lab Corp.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

BioNexus Gene Lab Corp.'s debt has increased relative to shareholder equity from 0.03 last year to 0.03 today, signaling weakened financials

BioNexus Gene Lab Corp. has a net cash position, so leverage is healthy.

BioNexus Gene Lab Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

BioNexus Gene Lab Corp.'s profit margin has decreased (225.47%) in the last year from -16.81% to -54.70%, signaling decreasing performance

BioNexus Gene Lab Corp.'s short-term assets of $5.45M exceed its short-term liabilities of $520.96K

BioNexus Gene Lab Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioNexus Gene Lab Corp.'s return on equity of -37.43%, is lower than 15.00%, indicating bad performance

BioNexus Gene Lab Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioNexus Gene Lab Corp. had positive net income in only 1 out of 5 years, indicating unstable earnings

BioNexus Gene Lab Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

BioNexus Gene Lab Corp. has negative free cash flow, indicating cash burn

BioNexus Gene Lab Corp.'s yearly earnings has decreased 86.73% since last year from $-1.60M to $-2.98M, signaling decreasing performance

BioNexus Gene Lab Corp.'s yearly revenue has decreased 21.93% since last year from $9.51M to $7.42M, signaling decreasing performance

ROIC -14.25% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioNexus Gene Lab Corp.'s 3-year revenue CAGR of -12.09% is negative, indicating declining revenue over the past 3 years

BioNexus Gene Lab Corp. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

BioNexus Gene Lab Corp. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

BioNexus Gene Lab Corp. has insufficient data to evaluate this check.

BioNexus Gene Lab Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioNexus Gene Lab Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioNexus Gene Lab Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioNexus Gene Lab Corp. has insufficient data to evaluate this check.

BioNexus Gene Lab Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioNexus Gene Lab Corp. has a price-to-book ratio of 0.47x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioNexus Gene Lab Corp. has a price-to-sales ratio of 0.71x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue